Week in Review: Week's China Life Science Deals Total $795 Million

Asymchem Laboratories of Tianjin raised $125 million in a Shenzhen IPO that it will use to expand its CMO operations; BeyondSpring Pharma, a virtual US-China cancer company, filed to stage a $100 million IPO on the NASDAQ exchange; SciClone Pharma, a US company marketing drugs in China, received an unsolicited $570 million acquisition offer from Ally Bridge affiliates; Uni-Bio Science of Hong Kong and Luqa Pharma of China formed a China dermatology co-marketing partnership; Omixon, a Budapest molecular diagnostics company, partnered with Taiwan's TBG Biotechnology to distribute Omixon's genotyping products in China; researchers at Chengdu's Sichuan University became the first to inject CRISPR–Cas9 edited genes into a patient; Athenex, a US-China pharma, will collaborate with Eli Lilly in a two-drug gastric cancer clinical trial; Hutchison China MediTech reported positive data from a first-in-human Phase I trial of a Syk inhibitor; ASLAN Pharma of Singapore engaged JHL Biotech of Taiwan and China to provide biologic process development services; and NeuroMetrix, a US medical device maker, announced it will launch its peripheral neuropathy diagnostic in China. More details.... Stock Symbols: (SHZ: OO2821) (NSDQ: SCLN) (HK: 0690) (NYSE: LLY) (AIM/NSDQ: HCM) (NSDQ: NURO) Share this with colleagues: // //